Global Lupus Therapeutic Market – Industry Trends and Forecast to 2029

Análise e dimensão do mercado

Nos últimos anos, prevê -se que o mercado terapêutico do lúpus cresça rapidamente durante o período de previsão. A Lupus Foundation of America estima que 1,5 milhões de americanos tenham lúpus, com 16 mil novos casos registados a cada ano nas Américas. O lúpus é uma doença auto-imune crónica na qual o sistema imunitário do corpo falha em identificar as suas próprias células e tecidos e ataca-os. O seu sistema imunitário ataca a sua pele no lúpus cutâneo. O lúpus cutâneo afeta cerca de 10% de todos os casos de lúpus, enquanto o lúpus cutâneo afeta 65% dos doentes com lúpus sistémico.

A pesquisa de mercado da Data Bridge analisa que o mercado terapêutico do lúpus foi avaliado em 2.562,05 milhões de dólares em 2021 e deverá atingir os 5.142,63 milhões de dólares em 2029, registando um CAGR de 9,10% durante o período de previsão de 2022 a 2029. O relatório de mercado. A equipa de pesquisa de mercado da Data Bridge inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Definição de mercado

O lúpus é uma condição inflamatória autoimune na qual o sistema imunitário do corpo se torna hiperativo e começa a atacar os tecidos saudáveis. Inchaço, inflamação, erupções cutâneas e desconforto articular são sinais e sintomas comuns do lúpus. As terapias de lúpus são um tipo de terapêutica que é frequentemente utilizada para tratar doenças de lúpus.

Âmbito do relatório e segmentação de mercado

Dinâmica do mercado terapêutico do lúpus

Motoristas

• Aumento da prevalência de lúpus

Prevê-se que a crescente prevalência do lúpus influencie o crescimento do mercado terapêutico do lúpus. O lúpus é uma doença auto-imune na qual o sistema imunitário do corpo se torna hiperactivo e tem como alvo o tecido normal e saudável. Inflamação, inchaço e danos nas articulações, pele, rins, sangue, coração e pulmões são alguns dos sintomas.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado terapêutico do lúpus é o aumento do gasto de saúde que ajuda a melhorar a sua infraestrutura.

Além disso, as crescentes iniciativas de organizações públicas e privadas para difundir a consciencialização irão expandir o mercado terapêutico do lúpus. Além disso, o elevado rendimento disponível e o aumento da procura por terapias eficazes resultarão na expansão do mercado terapêutico do lúpus. Juntamente com isto, o aumento da população geriátrica e a mudança contínua do estilo de vida aumentarão a taxa de crescimento do mercado.

Oportunidades

• Aumento do número de atividades de investigação e desenvolvimento       

Além disso, o crescimento do mercado é alimentado por um aumento do número de atividades de investigação e desenvolvimento. Isto proporcionará oportunidades benéficas para o crescimento do mercado terapêutico do lúpus. Juntamente com isto, o aumento das aprovações e lançamentos de medicamentos impulsionará ainda mais a taxa de crescimento do mercado.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the lupus therapeutic market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of lupus will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the lupus therapeutic market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This lupus therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lupus therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Lupus is far more common in women. Women between the ages of 15 and 44 make up over 90% of those diagnosed with lupus. It is, however, available to persons of all genders and ages. Lupus commonly appears in children at the age of 12.

Lupus therapeutic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Lupus Therapeutic Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of lupus therapeutic in recent months.

Recent Development

• In August 2021, AstraZeneca had announced the approval of Food and Drug Administration (FDA) for Saphnelo (anifrolumab) in the US. Saphnelo is a first-in-class type I interferon receptor antibody that is the first novel treatment for patients with systemic lupus erythematosus in more than a decade.

Global Lupus Therapeutic Market Scope

The lupus therapeutic market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Systemic Lupus Erythematosus (SLE)
• Cutaneous Lupus Erythematosus,
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus

Treatment

• Corticosteroids
• Immunosuppressive Drugs
• Biologic Drugs
• Antihypertensive Drugs
• Others

Diagnosis

• Laboratory Tests

• Antinuclear antibody (ANA) test
• Urinalysis
• Kidney and liver assessment
• Erythrocyte sedimentation rate
• Complete blood count

• Biopsy
• Imaging Tests

• Echocardiogram
• Chest X-ray

• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Lupus Therapeutic Market Regional Analysis/Insights

The Lupus therapeutic market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Lupus therapeutic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the lupus therapeutic market because of the growing prevalence of lupus in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Lupus Therapeutic Market Share Analysis

The Lupus therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lupus therapeutic market.

Some of the major players operating in the lupus therapeutic market are:

• LEO Pharma A/S (Denmark)
• Zydus Cadila (India)
• Amneal Pharmaceuticals LLC. (US)
• Glenmark Pharmaceuticals Limited (India)
• Hikma Pharmaceuticals PLC (UK)
• Dr. Reddy’s Laboratories Ltd. (India)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Bausch Health Companies Inc. (Canada)
• Eli Lilly and Company (US)
• AbbVie Inc. (US)
• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Allergan (Ireland)
• Merck & Co., Inc. (US)
• Sumitomo Corporation (Japan)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)

SKU-53306